Carriers of pathogenic or likely pathogenic (P/LP) variants in MYH7 generally present with an earlier onset of hypertrophic cardiomyopathy, more pronounced left ventricular hypertrophy, and an increased incidence of adverse outcomes, including ventricular arrhythmias and sudden cardiac death, particularly in individuals with a family history of early cardiac events. Here, MYH7 is linked to left ventricular hypertrophy.